These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15600307)

  • 1. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
    Sakurai K; Chung HS; Kahne D
    J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
    J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.
    Chen L; Yin H; Farooqi B; Sebti S; Hamilton AD; Chen J
    Mol Cancer Ther; 2005 Jun; 4(6):1019-25. PubMed ID: 15956260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of peptide retro-inverso isomerization in molecular mimicry.
    Li C; Pazgier M; Li J; Li C; Liu M; Zou G; Li Z; Chen J; Tarasov SG; Lu WY; Lu W
    J Biol Chem; 2010 Jun; 285(25):19572-81. PubMed ID: 20382735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aib-based peptide backbone as scaffolds for helical peptide mimics.
    Banerjee R; Basu G; Chène P; Roy S
    J Pept Res; 2002 Aug; 60(2):88-94. PubMed ID: 12102721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
    García-Echeverría C; Chène P; Blommers MJ; Furet P
    J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
    [No Abstract]   [Full Text] [Related]  

  • 10. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
    Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
    Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
    Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of potent non-peptide MDM2 inhibitors.
    Ding K; Lu Y; Nikolovska-Coleska Z; Qiu S; Ding Y; Gao W; Stuckey J; Krajewski K; Roller PP; Tomita Y; Parrish DA; Deschamps JR; Wang S
    J Am Chem Soc; 2005 Jul; 127(29):10130-1. PubMed ID: 16028899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
    Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
    Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site.
    Do TN; Rosal RV; Drew L; Raffo AJ; Michl J; Pincus MR; Friedman FK; Petrylak DP; Cassai N; Szmulewicz J; Sidhu G; Fine RL; Brandt-Rauf PW
    Oncogene; 2003 Mar; 22(10):1431-44. PubMed ID: 12629507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-phase synthesis of the cyclic peptide portion of chlorofusin, an inhibitor of p53-MDM2 interactions.
    Malkinson JP; Zloh M; Kadom M; Errington R; Smith PJ; Searcey M
    Org Lett; 2003 Dec; 5(26):5051-4. PubMed ID: 14682762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2.
    Sakurai K; Schubert C; Kahne D
    J Am Chem Soc; 2006 Aug; 128(34):11000-1. PubMed ID: 16925398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fluorescence polarization assay for the identification of inhibitors of the p53-DM2 protein-protein interaction.
    Knight SM; Umezawa N; Lee HS; Gellman SH; Kay BK
    Anal Biochem; 2002 Jan; 300(2):230-6. PubMed ID: 11779115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction.
    Fasan R; Dias RL; Moehle K; Zerbe O; Vrijbloed JW; Obrecht D; Robinson JA
    Angew Chem Int Ed Engl; 2004 Apr; 43(16):2109-12. PubMed ID: 15083458
    [No Abstract]   [Full Text] [Related]  

  • 19. Small molecule inhibitors of p53/MDM2 interaction.
    Fotouhi N; Graves B
    Curr Top Med Chem; 2005; 5(2):159-65. PubMed ID: 15853644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.